Ignite Creation Date:
2025-12-24 @ 9:33 PM
Ignite Modification Date:
2026-03-29 @ 3:41 AM
Study NCT ID:
NCT02346032
Status:
COMPLETED
Last Update Posted:
2017-04-26
First Post:
2014-11-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
Sponsor:
Samsung Medical Center